公开(公告)号：US10980859B2

公开(公告)日：2021-04-20

申请号：US15058456

申请日：2016-03-02

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Fang Hu ,  Ronghua Zhao ,  Siyi Chen ,  Bo Wu ,  Huiqun Xia ,  Yanjun Zheng

IPC: A61K38/19 ,  A61K35/761 ,  A61K45/06 ,  A61K31/513 ,  A61K31/7068 ,  A61K31/704 ,  A61K33/24 ,  A61K31/475 ,  A61K35/768 ,  A61K38/48 ,  A61K35/763 ,  A61K35/74 ,  A61K38/55 ,  A61K35/766 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  C12N7/00 ,  A61K39/00

Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.

公开(公告)号：US20160250292A1

公开(公告)日：2016-09-01

申请号：US15058456

申请日：2016-03-02

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Fang Hu ,  Ronghua Zhao ,  Siyi Chen ,  Bo Wu ,  Huiqun Xia ,  Yanjun Zheng

IPC: A61K38/19 ,  C12N7/00 ,  A61K39/395 ,  C07K16/30 ,  A61K35/761 ,  C07K16/28

CPC classification number: A61K38/193 ,  A61K31/475 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K35/74 ,  A61K35/761 ,  A61K35/763 ,  A61K35/766 ,  A61K35/768 ,  A61K38/191 ,  A61K38/4873 ,  A61K38/55 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/10332 ,  Y02A50/466 ,  Y02A50/484 ,  A61K2300/00

Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.

Abstract translation: 本发明提供一种体内个体化的全身免疫治疗方法和装置。 该方法以非顺序方式包括：（1）增加肿瘤部位肿瘤抗原的释放量; （2）在肿瘤部位，增加能够粘附和/或包裹肿瘤抗原的蛋白质水平; （3）在肿瘤部位增加参与免疫的专用抗原呈递细胞的水平，并且在专用抗原呈递细胞和免疫效应细胞之间建立能够激活免疫效应细胞的紧密连接; 和（4）在肿瘤部位，增加免疫效应细胞的水平和改善功能。 步骤（1） - （4）各自在最大相互重叠的相应时间以及最大重叠的相应位置处达到最大值。 本发明结合了溶瘤治疗和免疫治疗，在个体化的全身免疫治疗中，提供了显着改善的治疗效果。